Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
RK

Robert John Konrad — 8 Patents

Eli Lilly: 6 patents #573 of 2,858Top 25%
TFThe Uab Research Foundation: 1 patents #374 of 813Top 50%
Hoover, AL: #18 of 165 inventorsTop 15%
Alabama: #912 of 10,951 inventorsTop 9%
Overall (All Time): #600,572 of 4,157,543Top 15%
8 Patents All Time
Robert John Konrad has been granted 8 US patents while listed as an inventor at Eli Lilly. The first was granted in 2002 and the most recent in November 2025. Robert John Konrad ranks #600,572 of 4,157,543 US inventors in our database (top 14.4%). Patent records list Robert John Konrad in Hoover, AL, US.

Patents per Year

Patents granted per year, 2002 to 2024Bar chart with a peak of 2 patents in 2022.peak 22002: 1 patents20022003: 1 patents20032021: 1 patents20212022: 2 patents20222023: 1 patents20232024: 1 patents2024

Issued Patents All Time

Showing 1–8 of 8 patents

Patent #TitleCo-InventorsDateApprox Value ⓘ
12459997 Compounds and methods targeting interleukin-19 Richard Higgs, Brian J. Nickoloff, Robert W. Siegel 2025-11-04
12180270 Anti-ANGPTL 3/8 complex antibodies and methods of using the same Qing Chai, Jonathan Day, Yuewei Qian, Oliver Schroeder, Robert W. Siegel 2024-12-31 $5,059,904,000
11591387 Compounds and methods targeting interleukin-19 Richard Higgs, Brian J. Nickoloff, Robert W. Siegel 2023-02-28 $2,117,452,000
11492395 Polynucleotides for preparing ANGPTL 3/8 complexes Qing Chai, Jonathan Day, Yuewei Qian, Oliver Schroeder, Robert W. Siegel 2022-11-08 $1,119,265,000
11242383 Anti-ANGPTL ⅜ complex antibodies and methods of using the same Qing Chai, Jonathan Day, Yuewei Qian, Oliver Schroeder, Robert W. Siegel 2022-02-08 $760,237,000
10919959 ANGPTL3/8 complexes and methods of using the same Qing Chai, Jonathan Day, Yuewei Qian, Oliver Schroeder, Robert W. Siegel 2021-02-16 $1,845,849,000
6589995 Method of inhibiting pancreatic &bgr;-cell p135 O-glycosylation Jeffrey Kudlow 2003-07-08
6361995 Protection of pancreatic &bgr;-cells during islet isolation and assessment of islet viability and candidate diabetes drugs after islet isolation Jeffrey Kudlow 2002-03-26